Cancer Care Associates of York, INC.
Cancer Care Associates of York, INC. was paid $440K by Medicaid between Aug 2020 and Nov 2024, across 21 billing codes. Its largest line is 99215, doctor's office visit, returning patient (complex) — 44% of everything it billed.
33Billing provider infoCANCER CARE ASSOCIATES OF YORK, INC.
YORK, PA 17403
YORK, PA 17403
33aNPI1578587101assigned 07/27/2006
33bProvider typeSpecialist
28Total paid$440K
24GClaims16,265
24DCodes billed21
24AFirst – last monthAug 2020 – Nov 2024
Compared with peers
Next to other Specialist providers in Pennsylvania
Rank by total paid#26 of 543
Median peer was paid$16K
This provider vs. median28×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 844 | $23K | |
| 2021 | 5,968 | $233K | |
| 2022 | 3,226 | $71K | |
| 2023 | 3,604 | $69K | |
| 2024incomplete | 2,623 | $44K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 44% | 3,234 | 2,911 | $192K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 20% | 57 | 42 | $88K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 14% | 741 | 657 | $62K |
| 80053 | Comprehensive metabolic panel | 7.0% | 2,868 | 2,437 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.8% | 5,595 | 4,656 | $30K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.8% | 285 | 279 | $12K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 1.7% | 973 | 624 | $7K |
| 96367 | 1.4% | 347 | 303 | $6K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 27 | 27 | $4K |
| 99245 | <1% | 12 | 12 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 40 | 38 | $1K |
| 96417 | <1% | 13 | 12 | $937.96 |
9 more codes
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,283 | $840.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 82 | $787.38 |
| 82728 | <1% | 56 | $562.25 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 31 | $417.61 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 377 | $194.59 |
| 83540 | <1% | 14 | $118.75 | |
| 83550 | <1% | 14 | $70.25 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 156 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 60 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSOTIRESCU, DAN (PRESIDENT)